UA43332C2 - Сполука, що є похідним 2-амінобіцикло[3.1.0]гексан-2,6-дикарбонової кислоти, спосіб одержання цієї сполуки, фармацевтична композиція, що містить цю сполуку, проміжна сполука - Google Patents

Сполука, що є похідним 2-амінобіцикло[3.1.0]гексан-2,6-дикарбонової кислоти, спосіб одержання цієї сполуки, фармацевтична композиція, що містить цю сполуку, проміжна сполука

Info

Publication number
UA43332C2
UA43332C2 UA95083799A UA95083799A UA43332C2 UA 43332 C2 UA43332 C2 UA 43332C2 UA 95083799 A UA95083799 A UA 95083799A UA 95083799 A UA95083799 A UA 95083799A UA 43332 C2 UA43332 C2 UA 43332C2
Authority
UA
Ukraine
Prior art keywords
compound
aminobycycl
hexan
pharmaceutical
preparation
Prior art date
Application number
UA95083799A
Other languages
English (en)
Inventor
Девід Рід Хелтон
Джеймс Аллен Монн
Роджер Льюіс Роубі
Дарріл Дарвін ШЕПП
Джозеф Патрік Тіззано
Original Assignee
Елі Ліллі Енд Компані
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Елі Ліллі Енд Компані, Эли Лилли Энд Компани filed Critical Елі Ліллі Енд Компані
Publication of UA43332C2 publication Critical patent/UA43332C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30—Unsaturated compounds
    • C07C62/38—Unsaturated compounds containing keto groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Композиція інгредієнтів до горілки особливої містить спирт етиловий ректифікований, воду питну пом'якшену, ароматний спирт чебрецю, мед натуральний, додатково містить ароматний спирт меліси лікарської.
UA95083799A 1994-08-12 1995-08-14 Сполука, що є похідним 2-амінобіцикло[3.1.0]гексан-2,6-дикарбонової кислоти, спосіб одержання цієї сполуки, фармацевтична композиція, що містить цю сполуку, проміжна сполука UA43332C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28995794A 1994-08-12 1994-08-12
US33734994A 1994-11-10 1994-11-10
US08/496,643 US5750566A (en) 1994-08-12 1995-06-29 Synthetic excitatory amino acids

Publications (1)

Publication Number Publication Date
UA43332C2 true UA43332C2 (uk) 2001-12-17

Family

ID=26965934

Family Applications (1)

Application Number Title Priority Date Filing Date
UA95083799A UA43332C2 (uk) 1994-08-12 1995-08-14 Сполука, що є похідним 2-амінобіцикло[3.1.0]гексан-2,6-дикарбонової кислоти, спосіб одержання цієї сполуки, фармацевтична композиція, що містить цю сполуку, проміжна сполука

Country Status (5)

Country Link
US (2) US5661184A (uk)
KR (1) KR100375463B1 (uk)
BR (1) BR9503638A (uk)
CO (1) CO4410321A1 (uk)
UA (1) UA43332C2 (uk)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL182285B1 (pl) * 1994-08-12 2001-12-31 Lilly Co Eli Syntetyczne aminokwasy oraz ich estry i srodki farmaceutyczne je zawierajace PL PL PL PL PL PL PL
DE69523324T2 (de) * 1994-08-12 2002-07-04 Eli Lilly And Co., Indianapolis Behandlung von Angstzuständen
ZA969485B (en) * 1995-11-16 1998-05-12 Lilly Co Eli Excitatory amino acid receptor antagonists.
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
US5824662A (en) * 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
PL332413A1 (en) 1996-09-27 1999-09-13 Guilford Pharm Inc Compositions containing inhibitors of naaladase as well as methods of treating glutamatic anomaly and influencing neuronic functions among animals
ZA983930B (en) 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
US5891646A (en) * 1997-06-05 1999-04-06 Duke University Methods of assaying receptor activity and constructs useful in such methods
US7541151B2 (en) 1997-06-05 2009-06-02 Duke University Single-cell biosensor for the measurement of GPCR ligands in a test sample
US6528271B1 (en) 1997-06-05 2003-03-04 Duke University Inhibition of βarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia
US6124361A (en) * 1997-12-31 2000-09-26 Pfizer Inc Bicyclo[3.1.0]hexanes and related compounds
ES2191412T3 (es) 1998-01-28 2003-09-01 Taisho Pharmaceutical Co Ltd Derivados de aminoacidos que contienen fluor.
US6521561B1 (en) 1998-05-01 2003-02-18 President And Fellows Of Harvard College Main-group metal based asymmetric catalysts and applications thereof
DK1110943T3 (da) 1998-08-31 2004-10-11 Taisho Pharmaceutical Co Ltd 6-fluorbicyclo[3.1.0]hexanderivater
PE20001236A1 (es) * 1998-11-13 2000-11-10 Lilly Co Eli Moduladores del receptor de aminoacidos excitadores
JP4505926B2 (ja) * 1999-03-25 2010-07-21 大正製薬株式会社 新規カルボン酸誘導体及びその製造方法
WO2000058258A1 (en) * 1999-03-25 2000-10-05 Taisho Pharmaceutical Co., Ltd. Novel carboxylic acid derivatives and process for producing the same
JP4192331B2 (ja) * 1999-04-16 2008-12-10 住友化学株式会社 光学活性２−オキソビシクロ［３．１．０］ヘキサン−６−カルボン酸誘導体の製造方法
EP1310482A1 (en) * 2001-11-07 2003-05-14 Eli Lilly And Company Prodrugs of excitatory amino acids
WO2002055485A1 (en) * 2001-01-11 2002-07-18 Eli Lilly And Company Prodrugs of excitatory amino acids
HUP0400620A3 (en) * 2001-01-11 2012-09-28 Lilly Co Eli Prodrugs of excitatory amino acids and pharmaceutical compositions containing them and process for preparation the compounds
US20040248963A1 (en) * 2001-11-23 2004-12-09 Bueno Melendo Ana Belen Prodrugs of excitatory amino acids
US7456221B2 (en) * 2001-12-21 2008-11-25 Eli Lilly And Company Prodrugs of excitatory amino acids
US20040116489A1 (en) * 2002-02-12 2004-06-17 Massey Steven Marc Synthetic excitatory amino acids
US20030182669A1 (en) * 2002-03-19 2003-09-25 Rockman Howard A. Phosphoinositide 3-kinase mediated inhibition of GPCRs
US20050192273A1 (en) * 2002-04-03 2005-09-01 Johnson Bryan G. Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist
US7290215B2 (en) * 2002-06-03 2007-10-30 Microsoft Corporation Dynamic wizard interface system and method
DK2123630T3 (da) * 2003-06-26 2012-10-22 Braincells Inc 2-Amino-bicyclo[3.1.0]hexan-2,6-dicarboxylsyreesterderivat
MXPA05013869A (es) * 2003-07-02 2006-02-28 Astrazeneca Ab Metabolito de quetiapina.
US20090093461A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Methods of Treating Anxiety and Mood Disorders
US20060252743A1 (en) * 2005-01-07 2006-11-09 Astrazeneca Ab Method of treating sleep disorders
US20070117789A1 (en) * 2005-11-18 2007-05-24 Astrazeneca Ab Method of treatment
US20060217366A1 (en) * 2003-07-02 2006-09-28 Astrazeneca Ab Method of treating schizophrenia and other disorders
US20060217367A1 (en) * 2004-07-01 2006-09-28 Astrazeneca Ab Method of treating anxiety disorders
US20090093460A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Compositions
US20060217365A1 (en) * 2003-07-02 2006-09-28 Astrazeneca Ab Method of treating mood disorders
US20060229292A1 (en) * 2005-01-07 2006-10-12 Astrazeneca Ab Method of treating childhood disorders
CA2580730C (en) * 2003-09-25 2015-01-13 Cenomed, Inc. Tetrahydroindolone derivatives for treatment of neurological conditions
CN100475800C (zh) * 2003-11-07 2009-04-08 大正制药株式会社 二环[3.1.0]己烷衍生物的制备方法及其中间体
US20050107439A1 (en) * 2003-11-10 2005-05-19 Helton David R. Composition and method for treating emesis
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2009062134A1 (en) * 2007-11-09 2009-05-14 Cenomed Biosciences, Llc Treatment of post-traumatic stress disorder with tetrahydroindolone arylpiperazine compounds
US20090264443A1 (en) * 2008-04-18 2009-10-22 David Helton Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
ME01516B (me) 2008-06-20 2014-04-20 Astrazeneca Ab DERIVAT DIBENZOTIAZEPINA l NJEGOVA UPOTREBA
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP3661500B1 (en) 2017-07-31 2026-01-07 Novartis AG Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3532744A (en) * 1967-07-28 1970-10-06 American Home Prod 1- and 2-amino substituted indane and tetralene carboxylic acids
US3704312A (en) * 1970-10-30 1972-11-28 American Home Prod Bialicyclic amino acids
US3746495A (en) * 1971-06-01 1973-07-17 American Home Prod Anti-ulcer therapy
GB9325368D0 (en) * 1993-12-10 1994-02-16 Univ Bristol Organic compounds

Also Published As

Publication number Publication date
CO4410321A1 (es) 1997-01-09
US5661184A (en) 1997-08-26
US5750566A (en) 1998-05-12
KR100375463B1 (ko) 2003-04-23
BR9503638A (pt) 1996-05-28
KR960007545A (ko) 1996-03-22

Similar Documents

Publication Publication Date Title
BR9407910A (pt) Composto composiçao farmacêutica uso do composto processo de tratamento de distúrbios no sistema nervoso central e processo de preparaçao do composto
ES2157307T3 (es) Composicion topica que contiene un antagonista de sustancia p.
HUP9902460A3 (en) Novel substituted imidazole compounds, their use, method for their preparation and pharmaceutical compositions containing them
UA34428C2 (uk) Заміщені фенілімідазолідини, спосіб їх одержання, фармацевтична композиція, проміжні сполуки
EA199700032A1 (ru) Дезинфицирующий состав "велтолен"
LV12582A (en) Disinfecting composition
DE69705967D1 (de) Stabilisierte pharmazeutische zusammensetzungen und verfahren zu ihrer herstellung
RU94042697A (ru) Композиция ингредиентов для водки "янтарная"
DE69501183D1 (de) Feste orale pharmazeutische Zubereitung mit Gemfibrozil als aktiver Inhaltsstoff und Verfahren zur Herstellung
AU3868895A (en) Process for the preparation of furosemide
RU92006170A (ru) Водка особая "водочка царская"
DE3570970D1 (en) Antiseptic product and method for manufacturing this product
UA28909A (uk) Композиція інгредієнтів до горілки особливої "князь данило галицький"
MD1704G2 (ro) Rachiu special
MD1703G2 (ro) Rachiu special
DE69716833D1 (de) Phosphorigsäure-Derivate als Zwischenprodukte zur Herstellung von Hals-Derivaten
RO103501A2 (en) Medicinal mouth water concentrate
UA30021C2 (uk) Горілка особлива "фуршетна"
UA24876A (uk) Горілка особлива "мазепа"
UA28704A (uk) Композиція інгредієнтів до горілки особливої "галицька ювілейна"
BR9908155A (pt) Composto, composição farmacêutica, uso do composto, e, processo para intensificar cognição em um sujeito sofrendo de cognição diminuìda
UA28910C2 (uk) Композиція інгредієнтів до горілки "hадія"
UY24851A1 (es) Derivados de ácidos n-acil-alfa-aminados
UA21898C2 (uk) Композиція іhгредієhтов для лікеру "раhковий"
UA37437A (uk) Горілка "перша гільдія"